Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WATTS WATER TECHNOLOGIES INCWTS · Entity 44 | Chief Financial Officer | March 21, 2018 | March 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WATTS WATER TECHNOLOGIES INC
Report date March 21, 2018 · Filed March 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,651 |
Reported balance
After 2018-03-21 transaction · row 1
1 source rowRow 1 · 2018-03-21 · Tax withholding · Disposed 1,619 · Balance 29,651 F1: Represents the number of shares required to be withheld by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awards previously granted to the Reporting Person. The withholding of shares to cover tax withholding obligations is mandated by the terms of Reporting Person's restricted stock awards under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be withheld by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awards previously granted to the Reporting Person. The withholding of shares to cover tax withholding obligations is mandated by the terms of Reporting Person's restricted stock awards under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does not represent a discretionary trade by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 14,166 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 8, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-22 · Disposition to issuer · Disposed 7,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-22 · Disposition to issuer · Disposed 6,530 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-22 · Disposition to issuer · Disposed 3,737 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 26,023 |
Reported balance
After 2022-12-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-22 · Grant · Acquired 26,023 · Balance 26,023 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-22 · Disposition to issuer · Disposed 26,023 · Balance 0 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
F3: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 8, 2022.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option;
F5: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)
F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerPerformance Stock Units · Derivative | 26,023 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · derivative · entry 6 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,023 shares Expires not disclosed F6 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · kind: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · price: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.exercise_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.expiration_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | GrantPerformance Stock Units · Derivative | 26,023 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · derivative · entry 5 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,023 Underlying: Common Stock · 26,023 shares Expires not disclosed F6 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · kind: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · price: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.exercise_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.expiration_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,737 | Not disclosed Strike: $283.88 | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · derivative · entry 4 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,737 shares Expires 2031-05-25 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,530 | Not disclosed Strike: $223.90 | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · derivative · entry 3 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,530 shares Expires 2030-05-29 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,000 | Not disclosed Strike: $266.39 | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · derivative · entry 2 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2029-05-30 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 20:41 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerCommon Stock, $0.01 par value | 14,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-013029 · form4-12282022_011259.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F1 · shares: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · shares: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3 · shares: Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on November 8, 2022. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · price: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 16:28 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 1,548 | $373.99 | $578,936.52 |
DisclosureSEC source: 0001415889-22-011176 · form4-11082022_091120.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,379 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · price: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:48 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 67 | $380.20 | $25,473.22 |
DisclosureSEC source: 0001415889-22-011061 · form4-11032022_011151.xml · nonDerivative · entry 4 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,927 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · price: This price represents the sale price of the transactions on the reported date at $380.1973. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:48 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 191 | $379.35 | $72,455.79 |
DisclosureSEC source: 0001415889-22-011061 · form4-11032022_011151.xml · nonDerivative · entry 3 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,994 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · price: This price represents the sale price of the transactions on the reported date at $379.3497. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:48 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 479 | $378.64 | $181,367.51 |
DisclosureSEC source: 0001415889-22-011061 · form4-11032022_011151.xml · nonDerivative · entry 2 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,185 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F3 · price: This price represents the sale price of the transactions on the reported date at $378.6378. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 16:48 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 263 | $377.82 | $99,366.66 |
DisclosureSEC source: 0001415889-22-011061 · form4-11032022_011151.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,664 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $377.8200. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 16:03 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,000 | $300.00 | $300,000.00 |
DisclosureSEC source: 0001415889-22-008303 · form4-08052022_010853.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,927 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · shares: This price represents the sale price of the transactions on the reported date at $300.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:29 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 518 | $266.34 | $137,964.12 |
DisclosureSEC source: 0001415889-22-005930 · form4-05312022_020517.xml · nonDerivative · entry 4 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,927 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:29 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 1,154 | $266.34 | $307,356.36 |
DisclosureSEC source: 0001415889-22-005930 · form4-05312022_020517.xml · nonDerivative · entry 3 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,445 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:29 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock, $0.01 par value | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005930 · form4-05312022_020517.xml · nonDerivative · entry 2 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,599 F2 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. F2 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. Read SEC document |
| May 26, 2022 Filed May 31, 2022 17:29 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock, $0.01 par value | 4,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005930 · form4-05312022_020517.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,999 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:06 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 298 | $249.19 | $74,258.62 |
DisclosureSEC source: 0001415889-22-005794 · form4-05272022_010518.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,765 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 16:26 UTC | ABIOMED INC NASD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,000 | $333.00 | $333,000.00 |
DisclosureSEC source: 0001415889-22-003909 · form4-04062022_010410.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · VICE PRESIDENT, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,063 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · price: This price represents the sale price of the transactions on the reported date at $333.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:27 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock, $0.01 par value | 1,000 | $359.43 | $359,430.00 |
DisclosureSEC source: 0001179110-22-000334 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,063 F1 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · shares: This price represents the sale price of the transactions on the reported date at $359.43. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:28 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 1,549 | $349.76 | $541,778.24 |
DisclosureSEC source: 0001179110-21-009900 · edgar.xml · nonDerivative · entry 2 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,063 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:28 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 6,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009900 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,612 F4 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F4 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 29, 2021 Filed Jun 2, 2021 16:40 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 518 | $284.58 | $147,412.44 |
DisclosureSEC source: 0001179110-21-006228 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,637 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 25, 2021 Filed May 27, 2021 16:50 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock Option (right to buy) · Derivative | 3,737 | $0.00 Strike: $283.88 | $0.00 |
DisclosureSEC source: 0001179110-21-006016 · edgar.xml · derivative · entry 4 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,737 Underlying: Common Stock · 3,737 shares Expires 2031-05-25 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 25, 2021 Filed May 27, 2021 16:50 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 2,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006016 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,155 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25,2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 25,2022, May 25, 2023 and May 25, 2024, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 16, 2021 Filed May 18, 2021 17:12 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 310 | $268.56 | $83,253.60 |
DisclosureSEC source: 0001179110-21-005518 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,134 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 17:14 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 936 | $329.75 | $308,646.00 |
DisclosureSEC source: 0001179110-21-004403 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,444 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:36 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock Option (right to buy) · Derivative | 6,530 | $0.00 Strike: $223.90 | $0.00 |
DisclosureSEC source: 0001179110-20-006841 · edgar.xml · derivative · entry 3 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,530 Underlying: Common Stock · 6,530 shares Expires 2030-05-29 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:36 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006841 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,380 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 29, 2021, May 29, 2022 and May 29, 2023, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 29, 2021, May 29, 2022 and May 29, 2023, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 16, 2020 Filed May 19, 2020 16:29 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 310 | $184.92 | $57,325.20 |
DisclosureSEC source: 0001179110-20-006301 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,880 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 19:04 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 943 | $156.27 | $147,362.61 |
DisclosureSEC source: 0001179110-20-004832 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,190 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 16:47 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $266.39 | $0.00 |
DisclosureSEC source: 0001179110-19-007008 · edgar.xml · derivative · entry 2 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-05-30 F1 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F2 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 30, 2019 Filed Apr 10, 2020 19:04 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $266.39 | $0.00 |
DisclosureSEC source: 0001179110-20-004832 · edgar.xml · derivative · entry 2 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2029-05-30 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 16, 2019 Filed May 17, 2019 16:17 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 310 | $259.68 | $80,500.80 |
DisclosureSEC source: 0001179110-19-006269 · edgar.xml · nonDerivative · entry 3 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,133 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 16, 2019 Filed May 17, 2019 16:17 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 2,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006269 · edgar.xml · nonDerivative · entry 2 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,443 F2 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 16, 2018. One third of these restricted stock units vested on May 16, 2019 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F2 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 16, 2018. One third of these restricted stock units vested on May 16, 2019 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| April 09, 2019 Filed May 17, 2019 16:17 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock, $0.01 par value | 934 | $282.95 | $264,275.30 |
DisclosureSEC source: 0001179110-19-006269 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,354 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 16:52 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock, $0.01 par value | 6,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005585 · edgar.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of April 9, 2019, April 9, 2020 and April 9, 2021, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of April 9, 2019, April 9, 2020 and April 9, 2021, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| March 21, 2018 Filed Mar 23, 2018 01:04 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | Tax withholdingClass A Common Stock | 1,619 | $79.70 | $129,034.30 |
DisclosureSEC source: 0001225208-18-006606 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,651 F1 · kind: Represents the number of shares required to be withheld by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awards previously granted to the Reporting Person. The withholding of shares to cover tax withholding obligations is mandated by the terms of Reporting Person's restricted stock awards under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 13:51 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 5,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-006456 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,270 F1 · shares: Consists of shares of restricted stock that vest in three equal annual installments beginning on the first anniversary of the date of grant. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 13:20 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | SaleClass A Common Stock | 8,975 | $75.88 | $681,014.03 |
DisclosureSEC source: 0001225208-18-003194 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,129 Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 18:43 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | Tax withholdingClass A Common Stock | 2,923 | $72.45 | $211,771.35 |
DisclosureSEC source: 0001225208-18-002474 · doc4.xml · nonDerivative · entry 2 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,104 F2 · shares: Represents shares disposed to cover taxes upon the vesting of performance stock units granted to the Reporting Person on October 26, 2015. The disposition of shares to cover tax withholding obligations is required by the terms of the Reporting Person's grant agreement and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 18:43 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 6,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002474 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,027 F1 · shares: Represents shares issued to the Reporting Person as a result of the vesting of performance stock units granted to the Reporting Person on October 26, 2015 Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 20:07 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | Tax withholdingClass A Common Stock | 733 | $64.00 | $46,912.00 |
DisclosureSEC source: 0001225208-17-013015 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,274 F1 · kind: Represents the number of shares required to be withheld from the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awarded to the Reporting Person on July 27, 2015. The withholding of shares to cover tax withholding obligations is mandated by the terms of Reporting Person's restricted stock award under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 17:50 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | Tax withholdingClass A Common Stock | 3,233 | $61.30 | $198,182.90 |
DisclosureSEC source: 0001225208-17-007949 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,551 F1 · kind: Represents the number of shares required to be withheld from the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awarded to the Reporting Person on April 9, 2015. The withholding of shares to cover tax withholding obligations is mandated by the terms of the Reporting Person's restricted stock award under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 20:55 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | Tax withholdingClass A Common Stock | 798 | $60.45 | $48,239.10 |
DisclosureSEC source: 0001225208-17-006722 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,784 F1 · kind: Represents the number of shares required to be withheld from the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock awarded to the Reporting Person on March 21, 2016. The withholding of shares to cover tax withholding obligations is mandated by the terms of Reporting Person's restricted stock award under the Issuer's Second Amended and Restated 2004 Stock Incentive Plan and does notrepresent a discretionary trade by the Reporting Person. Read SEC document |
| March 21, 2017 Filed Jul 31, 2017 20:04 UTC Amendment | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 5,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-013007 · doc4a.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,038 F1 · kind: This amendment to Form 4 reports the grant on March 21, 2017 of a restricted stock award to the Reporting Person pursuant to the Company's annual equity award program. This transaction was inadvertently omitted from the transactions reported on the Reporting Person's Form 4 originally filed on March 22, 2017. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 21:43 UTC | WATTS WATER TECHNOLOGIES INC WTS · Entity 44 | GrantClass A Common Stock | 3,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-003400 · doc4.xml · nonDerivative · entry 1 Trapp Todd A · CIK 0001638242 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,582 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.